Roche's Tecentriq added to UK early access scheme in SCLC

11 June 2019

Tecentriq (atezolizumab) has been added to the UK’s Early Access to Medicines Scheme (EAMS) for use in combination with the chemotherapy agents carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC).

The Medicines and Healthcare Products Regulatory Agency explained in a report the reasons for the Roche (ROG: SIX) immuno-oncology drug’s inclusion in the scheme to bring earlier availability of promising new unlicensed medicines to patients with high unmet clinical need.

“In patients with extensive stage SCLC, while initial responses to chemotherapy are often good, most patients become resistant to chemotherapy and the prognosis is poor,” the report states.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK